Trial intelligence / Profile preview

ADC4022 in Moderate to Severe COPD

NCT00634413Phase 2Completed

Sponsor
Pulmagen Therapeutics
Start
Feb 2008
Primary completion
Dec 2008
Modality
Small Molecules
Countries
2
01

Overview

A Phase 2 trial of ADC4022 in chronic obstructive pulmonary disease (COPD), sponsored by Pulmagen Therapeutics. Started Feb 2008; status: completed.

02

Drugs

ADC4022
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on NCT00634413.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00634413.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call